Group 1 - The company announced the appointment of Ms. Jing Huan and Mr. Bai Zhizhong as members of the nomination committee, effective from August 27, 2025 [1] - It is proposed to appoint Mr. Bai Zhizhong as the company's Chief Independent Non-Executive Director, effective from August 27, 2025 [1]

Group 1 - The company announced the appointment of Ms. Jing Huan and Mr. Bai Zhizhong as members of the nomination committee, effective from August 27, 2025 [1] - It is proposed to appoint Mr. Bai Zhizhong as the company's Chief Independent Non-Executive Director, also effective from August 27, 2025 [1]

格隆汇8月27日丨兴科蓉医药(06833.HK)宣布，(i)敬欢女士及白志中先生获委任为提名委员会成员，自 2025年8月27日起生效；及(ii)建议委任白先生为公司首席独立非执行董事，自2025年8月27日起生效。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sinco Pharmaceuticals Holdings Limited 興科蓉醫藥控股有限公司 （根 據 開 曼 群 島 法 例 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6833） 截 至2025年6月30日止六個月的 中期業績公告 財務摘要 – 2 – 中期簡明綜合財務狀況表 2025年6月30日 | | | | | | | | | | | | | | | | | 2025年 | | | 2024年 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | | | | | | 6月30日 | ...

Sinco Pharmaceuticals Holdings Limited 兴科蓉医药控股有限公司 （根 據 開 曼 群 島 法 例 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6833） 興科蓉醫藥控股有限公司 （「本 公 司」） 提名委員會（「委 員 會」） 的職權範圍 成 員 秘 書 7. 委 員 會 的 秘 書 須 由 公 司 秘 書 出 任。如 公 司 秘 書 缺 席，則 其 正 式 委 派 代 表 或 任 何 由 出 席 委 員 會 會 議 的 成 員 所 選 出 的 人 士，將 出 席 委 員 會 會 議 及 記 錄 會 議 紀 錄。 – 1 – 1. 委員會必須由不少於三名由本公司董事會（「董事會」）委 任 的 成 員 組 成，委 員 會 的 大 部 分 成 員 必 須 為 本 公 司 的 獨 立 非 執 行 董 事。 2. 委 員 會 的 主 席 須 由 董 事 會 委 任，且 必 須 為 獨 立 非 執 行 董 事。 3. 委員會成員不得有個人經濟利益（作 為 本 公 司 股 東 除 外）或因交錯董事身 份 而 引 致 的 利 益 衝 突。 4. 董 事 會 及 委 員 會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sinco Pharmaceuticals Holdings Limited 興科蓉醫藥控股有限公司 （根 據 開 曼 群 島 法 例 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6833） 有 關 向關連人士提供財務援助的 關連交易的 補充公告 茲提述興科蓉醫藥控股有限公司（「本公司」）日期為2025年5月30日的公告（「該 公 告」），內 容 有 關 於2021年3月1日向黃祥彬先生提供本金額為5百萬港元的免息貸 款。除 本 公 告 另 有 界 定 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 補充資料 董 事 謹 此 提 供 有 關 貸 款 的 額 外 資 料。 1. 引致審批貸款的一連串事件 董 事 謹 此 宣 佈，貸 款 需 求 於2021年2月 底 產 生，當 時 正 值 香 港 ...

Core Viewpoint - The company, Xingke Rong Pharmaceutical, has announced a board meeting scheduled for August 27, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if applicable [1] Group 1 - The board meeting will take place on August 27, 2025 [1] - The meeting will focus on the approval of interim results for the six months ending June 30, 2025 [1] - The company will also consider the proposal for an interim dividend during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 Sinco Pharmaceuticals Holdings Limited 興科蓉醫藥控股有限公司 董事會會議召開日期 興科蓉醫藥控股有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司將於二零二五年八月二十七日（星 期 三）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考 慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業 績 及 其 刊 發，並 考 慮 建 議 派 發 中 期 股 息（如 有）。 承董事會命 興科蓉醫藥控股有限公司 主席兼執行董事 黃祥彬 中 國 四 川，二 零 二 五 年 八 月 十 五 日 於 本 公 告 日 期，執 行 董 事 為 黃 祥 彬 先 生、雷 世 峰 先 生 及 黃 智 健 先 生；非 執 行 董 事 為 敬 歡 女 士 及 獨 立 非 執 行 董 事 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 公司名稱: 興科蓉醫藥控股有限公司 (根據開曼群島法例註冊成立的有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06833 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.0001 | HKD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.0001 | HKD | | 1,000,000 | 本月底法定/註冊股 ...

Financial Performance - The Group's revenue increased by 11.1% or RMB 281.2 million to RMB 2,821.3 million for the Reporting Period (2023: RMB 2,540.1 million) driven mainly by increased sales volume of human albumin solution[13] - Gross profit decreased by RMB 23.4 million to RMB 299.9 million, with a gross profit margin decline from 12.7% in 2023 to 10.6% due to rising costs outpacing revenue growth[13] - Net profit for the Group was RMB 42.0 million, a slight decrease of RMB 0.4 million compared to RMB 42.4 million in 2023, representing a 0.9% decline[13] - Basic and diluted earnings per share remained at RMB 0.02 for the Reporting Period, unchanged from 2023[13] - Profit before tax for the Reporting Period was RMB 98.9 million, slightly down from RMB 99.9 million in 2023[14] - The net profit margin for the year was 1.5%, down from 1.7% in 2023[14] - Revenue from sales of human albumin solution increased by approximately RMB 276.5 million, primarily due to higher sales volume[13] - Revenue from human albumin solution reached RMB2,782.7 million, an increase of approximately 11.0% or RMB257.6 million compared to 2023[40] - Revenue from medical beauty services amounted to RMB28.7 million, representing a growth of approximately 10.8% or RMB2.8 million compared to 2023[40] - Cost of sales increased to RMB2,521.4 million, up RMB304.6 million or 13.7% from RMB2,216.8 million in 2023[41] - Gross profit decreased to RMB299.9 million, down RMB23.4 million from RMB323.3 million in 2023, resulting in a gross profit margin decline from 12.7% to 10.6%[42] Dividends and Shareholder Information - The Board proposed a final dividend of HK$0.20 cents per ordinary share, totaling HK$4,000,000, down from HK$8,000,000 in 2023[13] - The final dividend declared for the year ended December 31, 2024, is HK$0.20 per ordinary share, totaling HK$4,000,000, a decrease from HK$8,000,000 in 2023[187] - The annual general meeting is scheduled for May 15, 2025, where shareholders will vote on the proposed final dividend[188] - The final dividend will be paid on or around June 3, 2025, subject to shareholder approval at the AGM[196] - The record date for entitlement to the final dividend is May 23, 2025[200] Assets and Liabilities - The Group's total assets increased from RMB1,424,333 thousand in 2022 to RMB1,890,678 thousand in 2023, reflecting a growth of 32.7%[18] - The total equity attributable to owners rose from RMB603,812 thousand in 2022 to RMB628,052 thousand in 2023, an increase of 4.0%[18] - The Group's cash and cash equivalents were RMB657,948 thousand in 2023, projected to decrease to RMB411,377 thousand in 2024[18] - Trade receivables decreased slightly to RMB509.7 million, down RMB26.3 million or 4.9% from RMB536.0 million in 2023[58] - Trade payables and bills payable as of December 31, 2024, totaled RMB 888.0 million, reflecting an increase of RMB 21.4 million from RMB 866.6 million as of December 31, 2023, mainly due to increased payables for human albumin injections[70] - The Group's total borrowings as of December 31, 2024, amounted to RMB 340.9 million, up from RMB 241.7 million in 2023, with current bank loans increasing to RMB 340.9 million from RMB 240.9 million[73] - The gearing ratio at the end of the reporting period was 57.5%, up from 47.2% in 2023, indicating an increase in the proportion of debt relative to equity[75] Operational Highlights - The annual batch release volume of human albumin reached 83.2 million bottles in 2024, representing a year-on-year increase of 6.5%[23] - The market share of imported albumin increased to 68.3% in 2024, enhancing the Group's industry influence and market share in this segment[23] - The Group's cold chain storage facilities in Chengdu officially commenced operations in 2024, significantly enhancing storage and distribution capacity[30] - The first phase of the cold chain storage facilities in Chengdu has commenced full operation, occupying 15,000 square meters, with a Phase II expansion expected to add 18,000 square meters by 2025[107] - The introduction of a digital supply chain system has improved operational efficiency and reduced logistics costs[108] Research and Development - The Group plans to deepen its investment in research and development for new medical aesthetic products while advancing the commercialization of existing projects[29] - The Girl Needle project is expected to complete clinical trials in the fourth quarter of 2025, indicating ongoing innovation in medical aesthetic products[28] - The Group's R&D efforts include advancing the Girl Needle project, with clinical trials expected to complete in Q4 2025[109] Management and Governance - The company has a diverse leadership team with extensive experience in pharmaceuticals, finance, and human resources management[151][153][158][160][164] - The Company has a strong management team with diverse backgrounds in finance, pharmaceuticals, and technical consulting[173][177][171][178] - The management team is committed to driving innovation and product development in the pharmaceutical sector[173][178] - The Company aims to expand its market presence and improve operational efficiency through strategic management[173][178] Market Strategy - The Group aims to optimize its market layout and strengthen its marketing network, particularly in second- and third-tier cities[24] - The Group aims to enhance market coverage of human albumin by deepening cooperation with major medical institutions and optimizing supply chain management[114] - The Group is focused on commercializing core products like Girl Needle and expanding into international markets, particularly Southeast Asia[115] - The Group intends to accelerate the commercialization of key medical aesthetic products, particularly in high-end markets in major domestic cities, while expanding into Southeast Asia[118] Corporate Social Responsibility - The Group is committed to corporate social responsibility, supporting public welfare and contributing to the healthcare industry[117][119] - The Group has not incurred any material costs for compliance with environmental laws during the reporting period[135] Risk Management - The Group is focused on risk management, identifying potential risks such as supplier relationships and exchange rate fluctuations[127][128] - The Group's largest supplier accounted for 99.78% of total products purchased during the Reporting Period, indicating a high dependency on a single supplier[198]